Working… Menu

A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02985190
Recruitment Status : Recruiting
First Posted : December 7, 2016
Last Update Posted : May 27, 2019
Information provided by (Responsible Party):
Groupe Francophone des Myelodysplasies

Brief Summary:
This study is a phase II of effcicacy and tolerance of azacitidine in patients with myelodysplatic syndrome and steroid dependent or resistent systemic auto-immune and inflammatory disorders

Condition or disease Intervention/treatment Phase
MDS Systemic Autoimmune Diseases Drug: Azacitidine Phase 2

Detailed Description:
This trial will be a prospective French nationwide study analyzing the effect of treatment with azacitidine in patients with MDS-associated SAID with steroid dependence and/or resistance, and its correlation with possible changes in immunological parameters

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Efficacy and Tolerance of Azacitidine (AZA) In MDS-associated Steroid Dependent/Refractory Systemic Auto-immune and Inflammatory Disorders (SAID)
Actual Study Start Date : January 26, 2017
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : February 2023

Arm Intervention/treatment
Experimental: Azacitidine 75mg/m²/day

Azacitidine 75mg/m²/j subcutaneously daily for 7 days every 4 weeks for a minimum of 6 cycles (unless overt disease progression, especially to Acute Myeloid Leukemia (AML) occure before 6 cycles) Azacitidine will be continued after 6 cycles

  • in patients with hematological response of myelodysplastic syndrome to azacitidine according to IWG2006 criteria by 6 cycles (Complete Response (CR), Partial Response (PR), marrow Complete Response (CRm), stable disease with Hematological Improvment (HI)), for another 6 cycles
  • in patients with complete or partial response of Systemic Auto-Immune Disorders (SAID) after 6 cycles of Azacitidine, even if Myelodysplastic Syndrome remains only stable per IWG2006 criteria
Drug: Azacitidine
Azacitidine at 75mg/m²/j for 7 days.
Other Name: Vidaza

Primary Outcome Measures :
  1. Overall response rate of Myelodysplastic syndrome and systemic autoimmune and inflammatory diseases (SAID) [ Time Frame: 6 months ]
    Overall response rate (including partial and complete response) of systemic autoimmune and inflammatory diseases associated with Myelodysplastic syndrome after 6 cycles of azacitidine

Secondary Outcome Measures :
  1. Number of participants with treament-related adverse events as assessed by CTCAE v4.0 [ Time Frame: up to 52 weeks ]

Other Outcome Measures:
  1. Overall survival [ Time Frame: 24 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must understand and voluntarily sign the informed consent form
  • Age 18 years at the time of signing the informed consent form
  • Must be able to adhere to the study visit schedule and other protocol requirements
  • MDS or CMML or AML with 20-30% marrow blasts using 2008 WHO classification, with any of the following characteristics :

    1. IPSS intermediate 2 or high, including AML with 20 to 30% marrow blasts and CMML with WBC<13G/L and marrow blasts >10%,
    2. IPSS low or int 1 in need of treatment (transfusion dependent anemia resistant to ESAs and/or platelets below 30 G/l or below 50 G/l with bleeding or platelet transfusion requirement, and/or ANC < 0.5 G/l with infectious complications)
    3. Documented (by cytogenetic or molecular analysis) MDS /CMML not meeting those criteria, but with at least one significant cytopenia (Hb <10 g/dl, platelets <50G/l, ANC <1 G/l). In this situation, the underlying SAID should be severe and have resisted to a second line treatment (following steroids), if such treatment can be proposed for this particular SAID. Those cases should be discussed prior to inclusion with the trial sponsors complications)
  • SAID-associated with MDS defined according to usual international criteria for each SAID (ie ACR criteria for systemic lupus, Chapel Hill classification for systemic vasculitis, etc…)
  • Steroid dependence and/or resistance of SAID (steroid dependence being defined as the impossibility to decrease steroids during at least 2 months below 15 mg/day; steroid resistance as no response of SAID to at least 1 mg/kg/day of prednisone equivalent during one month)
  • Ineligibility for allogeneic stem cell transplantation during the following 12 months
  • Wash-out at least 6 months since a previous treatement with Lenalidomide
  • No previous use of hypomethylating agents
  • Life expectancy ≥ 6 months
  • Adequate liver function (serum transaminases ≤ 3N)
  • Adequate renal function (creatinine clearance with MDRD formula > 30 ml/min)
  • Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must :

    • Have a negative serum or urine pregnancy test within 2 weeks prior to beginning treatment on this study. Lactating patients are excluded.
    • Agree to use, and to be able to comply with, effective contraception without interruption, 4 weeks before starting study drug throughout the entire duration study drug therapy (including doses interruptions) and for 3 months after the end of the study drug therapy.
  • Male patients must :

    • Agree the need for the use of a condom if engaged in sexual activity with a woman of childbearing potential during the entire period of treatment, even if disruption of treatment and during 3 months after end of treatment.
    • Agree to learn about the procedures for preservation of sperm before starting treatment.

Exclusion Criteria:

  • IPSS low and intermediate-1 not meeting the criteria described above
  • Creatinine clearance with MDRD formula < 30 ml/min
  • Serum total bilirubin, or serum transaminases > 3.0 x upper limit of normal (ULN) (except for unconjugated hyperbilirubinemia due to Gilbert's disease or secondary to MDS)
  • Known hypersensitivity to the active substance or to any of the excipients of AZA
  • History of severe congestive heart failure, clinically unstable cardiac or pulmonary disease
  • Previous treatment with hypomethylating agents
  • Life-expectancy of less than six months because of another debilitating disease
  • Uncontrolled invasive fungal infection at time of registration or active serious infection not controlled by oral or intravenous antibiotics
  • Known positive for HIV or acute infectious hepatitis, type B or C
  • Any serious medical condition or psychiatric illness that will prevent the subject from signing the informed consent form or will place the subject at unacceptable risk if he/she participates in the study.
  • Active cancer or prior history of malignancy other than MDS (except basal cell or squamous cell carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been free of disease for ≥ 3 years
  • Pregnant or lactating females
  • No affiliation to an insurance system

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02985190

Layout table for location contacts
Contact: Arsene MEKINIAN, MD +33 1 49 28 21 04
Contact: Pierre FENAUX, PHD +33 1 71 20 70 22

  Show 57 Study Locations
Sponsors and Collaborators
Groupe Francophone des Myelodysplasies
Layout table for investigator information
Principal Investigator: Arsene MEKINIAN, MD Saint Antoine Hospital
Principal Investigator: Olivier FAIN, PHD Saint Antoine Hospital
Study Director: Pierre FENAUX, PHD Saint-Louis Hospital, Paris, France

Layout table for additonal information
Responsible Party: Groupe Francophone des Myelodysplasies Identifier: NCT02985190     History of Changes
Other Study ID Numbers: GFM-AZA-SAID
2016-000918-30 ( EudraCT Number )
First Posted: December 7, 2016    Key Record Dates
Last Update Posted: May 27, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Groupe Francophone des Myelodysplasies:
Systemic auto-immune and inflammatory disorders
Additional relevant MeSH terms:
Layout table for MeSH terms
Autoimmune Diseases
Immune System Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors